Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-30 02:00 |
Spexis informiert über die aktuelle Geschäftsentwicklung und gibt Finanzergebni…
|
German | 18.4 KB | ||
| 2023-04-28 07:20 |
Spexis has received temporary approval of an extension until 31 of May 2023 for…
|
English | 15.1 KB | ||
| 2023-04-28 02:00 |
Spexis has received temporary approval of an extension until 31 of May 2023 for…
|
English | 12.3 KB | ||
| 2023-04-28 02:00 |
Spexis erhält vorläufige Genehmigung für eine Ausnahme bzw. Befreiung von der O…
|
German | 12.7 KB | ||
| 2023-04-18 07:15 |
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Gl…
|
English | 12.4 KB | ||
| 2023-04-18 02:00 |
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Gl…
|
English | 10.5 KB | ||
| 2023-04-18 02:00 |
Spexis gibt den Abschluss einer Kapitalzusage in Höhe von 4,5 Mio. USD von SPRI…
|
German | 11.2 KB | ||
| 2023-02-08 07:20 |
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Par…
|
English | 15.3 KB | ||
| 2023-02-08 01:00 |
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Par…
|
English | 13.2 KB | ||
| 2023-02-08 01:00 |
Spexis und SPRIM Global Investments (SGI) geben Pläne für eine Partnerschaft zu…
|
German | 14.8 KB | ||
| 2023-01-09 07:15 |
Spexis reports solid safety and pharmacokinetics results from first-in-human st…
|
English | 11.7 KB | ||
| 2023-01-09 01:00 |
Spexis reports solid safety and pharmacokinetics results from first-in-human st…
|
English | 9.7 KB | ||
| 2023-01-09 01:00 |
Spexis gibt gute Verträglichkeits- und Pharmakokinetik-Ergebnisse der ersten kl…
|
German | 11.4 KB | ||
| 2022-12-13 07:30 |
Spexis announces promising pre-clinical data with balixafortide in combination …
|
English | 14.4 KB | ||
| 2022-12-13 01:00 |
Spexis announces promising pre-clinical data with balixafortide in combination …
|
English | 12.1 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
